Table 1 Baseline patient and treatment characteristics
Number of patients | 44 |
|---|---|
Demographics: | |
Age (years) [Median; IQR] | 37 (29, 51) |
Sex [n, %] | |
Male | 43 (98) |
Female | 0 (0) |
Transgender | 1 (2) |
Race/Ethnicity [n, %] | |
White | 26 (59) |
Black | 4 (9) |
Asian | 2 (5) |
Hispanic | 7 (16) |
Other | 5 (11) |
Hemophilia [n, %] | |
A | 35 (80) |
B | 9 (20) |
Hemophilia severity [n, %] | |
Mild | 3 (7) |
Moderate | 4 (9) |
Severe | 37 (84) |
Treatment: | |
Hemophilia Primary Therapy [n, %] | |
Clotting factor-based therapy | 40 (90) |
Prophylaxis | 38 (95) |
For ≥ 6 months | 34 (89) |
For < 6 months | 3 (11) |
On demand | 2 (5) |
Gene therapy | 2 (4.5) |
Emicizumab | 2 (4.5) |
Pain/Anti-inflammatory medications [n, %] | 18 (41) |
Anti-inflammatory medications | 5 (28) |
Acetaminophen | 2 (11) |
Opioids | 8 (44) |
Anti-inflammatory medications and opioids | 2 (11) |
Other | 1 (6) |